Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Apr 16, 2020

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results

SOUTH PLAINFIELD, N.J. , April 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial results and provide an update on the company's business and outlook on Thursday, April 30,

Apr 07, 2020

PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)

- U.S. Food and Drug Administration (FDA) extends review of risdiplam by three months following submission of additional data - - Risdiplam has been studied across a broad real-world population of infants, children, teenagers and adults with Type 1, 2 or 3 SMA - - European Medicine Agency (EMA)

Mar 16, 2020

PTC Therapeutics Announces Management Change

SOUTH PLAINFIELD, N.J. , March 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza , Chief Operating Officer, has resigned and will be leaving the company by April 25 th , 2020. "We are grateful to Marcio for the significant contributions he has made to

Mar 11, 2020

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , March 11, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 6, 2020 it approved non-statutory stock options to purchase an aggregate of 103,750 shares of its common stock to 35 new employees.

Mar 02, 2020

PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

SOUTH PLAINFIELD, N.J. , March 2, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019 . "2019 was a year of outstanding execution for PTC.

Feb 25, 2020

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , Feb. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present at the following conferences: Cowen 40 th Annual Health Care Conference Wednesday, March 4 th at 10:40 a.m. ET Barclays Global Healthcare Conference Tuesday,

Feb 18, 2020

PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy

- 28 initiatives improving the lives of those with Duchenne supported by the STRIVE Awards to date - - Grant funding proposals from non-profit patient advocacy organizations due April 30 - SOUTH PLAINFIELD, N.J. , Feb. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

Feb 17, 2020

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

SOUTH PLAINFIELD, N.J. , Feb. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and outlook on

Feb 06, 2020

SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

- Statistically significant results in primary and key secondary endpoints - - Risdiplam is the first SMA treatment to have positive placebo-controlled data in pivotal studies across a real world population of infants, children, teenagers and adults - - Investor call at 8am ET - SOUTH PLAINFIELD,

Feb 03, 2020

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 29, 2020 it approved non-statutory stock options to purchase an aggregate of 182,150 shares of its common stock to 57 new employees.

Pagination

First page
Previous page
…
Page 21
Page 22
Current page 23
Page 24
Page 25
…
Next page
Last page